Lipocine Historical Cash Flow
| LPCN Stock | USD 4.45 0.03 0.68% |
Analysis of Lipocine cash flow over time is an excellent tool to project Lipocine future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 1.9 M or Capital Expenditures of 12.5 K as it is a great indicator of Lipocine ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Lipocine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lipocine is a good buy for the upcoming year.
Lipocine |
About Lipocine Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Lipocine balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Lipocine's non-liquid assets can be easily converted into cash.
Lipocine Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Lipocine's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Other Cashflows From Investing Activities is very stable compared to the past year. As of the 28th of November 2024, Stock Based Compensation is likely to grow to about 1.1 M, while Free Cash Flow is likely to drop (12.5 M).
Lipocine cash flow statement Correlations
Click cells to compare fundamentals
Lipocine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lipocine cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.7M | 9.5M | (21.3M) | 197.9K | 1.6M | 1.7M | |
| Free Cash Flow | (11.7M) | (15.3M) | (4.4M) | (12.1M) | (11.9M) | (12.5M) | |
| Change In Working Capital | 469.3K | 1.5M | (4.6M) | (923.6K) | 2.0M | 2.1M | |
| Other Cashflows From Financing Activities | 56.4K | 7.7M | 11.7K | 211.4K | 13.1M | 6.9M | |
| Other Non Cash Items | 221.2K | 109.3K | 53.8K | (932.1K) | 1.8M | 1.9M | |
| Total Cash From Operating Activities | (11.7M) | (15.3M) | (4.4M) | (12.0M) | (11.9M) | (12.5M) | |
| Net Income | (13.0M) | (21.0M) | (634.4K) | (10.8M) | (16.4M) | (17.2M) | |
| Total Cash From Financing Activities | 10.3M | 20.9M | 26.9M | (2.1M) | 404.6K | 384.3K | |
| End Period Cash Flow | 14.7M | 24.2M | 3.0M | 3.1M | 4.8M | 4.5M | |
| Change To Netincome | 799.4K | 4.0M | 248.1K | (296.0K) | (340.4K) | (323.4K) | |
| Sale Purchase Of Stock | 13.7M | 13.3M | 26.9M | (21.7K) | (25.0K) | (23.7K) | |
| Begin Period Cash Flow | 13.1M | 14.7M | 24.2M | 3.0M | 3.1M | 3.0M | |
| Total Cashflows From Investing Activities | 3.0M | 3.9M | (43.8M) | 14.3M | 12.9M | 13.5M | |
| Depreciation | 15.4K | 3.6K | 380.0 | 9.5K | 28.7K | 30.1K | |
| Cash And Cash Equivalents Changes | 9.9M | 1.7M | 9.5M | (21.3M) | (19.1M) | (18.2M) | |
| Change To Liabilities | 473.1K | 1.6M | (944.6K) | (689.0K) | (620.1K) | (589.1K) | |
| Stock Based Compensation | 1.0M | 1.4M | 603.9K | 636.1K | 654.4K | 1.1M | |
| Cash Flows Other Operating | (1.0M) | (25.8K) | (115.4K) | (3.4M) | (3.1M) | (2.9M) | |
| Investments | 3.0M | 3.9M | (43.8M) | 14.3M | 13.0M | 13.6M | |
| Change To Operating Activities | (41.6K) | 1.1M | (4.3M) | (452.7K) | (407.5K) | (427.8K) | |
| Change Receivables | (15.4K) | 22.0K | 16.1K | (246.9K) | (222.2K) | (211.1K) | |
| Net Borrowings | (3.3M) | (1.4M) | (3.3M) | (2.3M) | (2.1M) | (2.0M) | |
| Issuance Of Capital Stock | 13.6M | 14.7M | 30.2M | (5.1K) | 404.6K | 384.3K |
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving against Lipocine Stock
| 0.74 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.65 | INKT | Mink Therapeutics | PairCorr |
| 0.63 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.62 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.6 | RGNX | Regenxbio | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.